spesolimab
LEO Pharma elects Henriette Mersebach to the Board of Directors
Mersebach previously held senior leadership positions at ALK-Abelló and Novo Nordisk
LEO Pharma acquires rights for dersimelagon from Tanabe Pharma
The company will pay $435m in up front and near-term milestone payments
Boehringer Ingelheim’s Jascayd approved by MHRA for idiopathic pulmonary fibrosis
This is the first treatment breakthrough in pulmonary fibrosis in over a decade
Oxford BioTherapeutics announces clinical milestones from its collaboration with Boehringer Ingelheim
The collaboration began in 2013 and was later expanded in 2020 and 2023
LEO Pharma and Allergy UK launch ‘Don’t Ignore’ chronic hand eczema campaign
The campaign aims to improve awareness and understanding of the condition
Boehringer and Immunitas agree on licensing deal for chronic inflammatory and autoimmune diseases
The agreement strengthens Boehringer Ingelheim’s growing immunology pipeline
LEO Pharma to acquire Replay gene therapy platform
The acquisition will advance innovation for patients with rare skin diseases
Matt Ferriday announced as General Manager for LEO Pharma UK
Ferriday most recently held senior leadership roles at Ipsen Biopharma
Almirall celebrates new offices in China to advance innovation in dermatology
The company’s R&D and commercial expertise represent valuable capabilities for future Chinese partners
LEO Pharma’s Anzupgo cream progresses to phase 3 trial for lichen sclerosus
There are currently no approved treatments specifically indicated for LS in the US or Europe
Boehringer Ingelheim and Simcere announce inflammatory bowel disease collaboration
There are more than three million people affected by IBD globally, with a need to improve current treatments
LEO Pharma receives NICE approval for chronic hand eczema cream
The cream can now be prescribed for patients when topical corticosteroids have not worked or are not suitable